An Unexpected Ally in Heart Failure Treatment: Unlocking the Potential of Sodium-Glucose Cotransporter 2 Inhibitors across Patient Subpopulations

Virtual Issues
21 November 2024
22 November 2024
Export Citation(s)Download PDF(s)

Table of Contents

Open Access

An unexpected ally in heart failure treatment: Unlocking the potential of sodium-glucose cotransporter 2 inhibitors across patient subpopulations

Sander Trenson,  Mateusz Sokolski, 
Open Access

Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events

Buena Aziri,  Edin Begic,  Slobodan Jankovic,  Zorica Mladenovic,  Bojan Stanetic,  Tamara Kovacevic-Preradovic,  Amer Iglica,  Aida Mujakovic, 
Open Access

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction

John S. Clemmer,  Taylor J. Ward,  Seth T. Lirette, 
Open Access

Sodium-glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure

Patric Karlström,  Aldina Pivodic,  Ulf Dahlström,  Michael Fu, 
Open Access

Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis

Hamidreza Soleimani,  Behrad Saeedian,  Yeganeh Pasebani,  Nastaran Babajani,  Amirreza Pashapour Yeganeh,  Pegah Bahirai,  Hossein Navid,  Ahmad Amin,  Marc D. Samsky,  Micheal G. Nanna,  Kaveh Hosseini, 
Open Access

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods

Hai-Bin Chen,  Yao-Lin Yang,  Rong-Sen Meng,  Xue-Wei Liu, 
Open Access

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure

Agnes Bosch,  Marko Poglitsch,  Dennis Kannenkeril,  Julie Kolwelter,  Kristina Striepe,  Christian Ott,  Manfred Rauh,  Mario Schiffer,  Stephan Achenbach,  Roland E. Schmieder, 
Open Access

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction

Luis Ortega-Paz,  Helena Cristóbal,  José Tomás Ortiz-Perez,  Pablo García de Frutos,  Guiomar Mendieta,  Elena Sandoval,  Juan José Rodriguez,  Emilio Ortega,  Ana García-Álvarez,  Salvatore Brugaletta,  Manel Sabaté,  Ana Paula Dantas, 
Open Access

Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling

Raj Verma,  Michael Moroney,  Makoto Hibino,  Cyril David Mazer,  Kim A. Connelly,  Andrew T. Yan,  Adrian Quan,  Hwee Teoh,  Subodh Verma,  Pankaj Puar, 
Open Access

IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial

Pankaj Puar,  Nikhil Mistry,  Kim A. Connelly,  Andrew T. Yan,  Adrian Quan,  Hwee Teoh,  Yi Pan,  Raj Verma,  David A. Hess,  Subodh Verma,  C. David Mazer, 
Open Access

Impact of diabetes duration on left ventricular mass regression with empagliflozin

Michael Moroney,  Raj Verma,  Makoto Hibino,  C. David Mazer,  Kim A. Connelly,  Andrew T. Yan,  Adrian Quan,  Hwee Teoh,  Subodh Verma,  Pankaj Puar, 
Open Access

Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort

Monika Beles,  Imke Masuy,  Sofie Verstreken,  Jozef Bartunek,  Riet Dierckx,  Ward Heggermont,  Clara Oeste,  Marieke De Boeck,  Isabelle Fovel,  Michael Maris,  Zarha Vermeulen,  Marc Vanderheyden, 
Open Access

Sodium-glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease

Shingo Kato,  Nobuyuki Horita,  Daisuke Utsunomiya, 
Open Access

Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i

Massimo Mapelli,  Valentina Mantegazza,  Cristina Ferrari,  Roberto Cimino,  Riccardo Maragna,  Gianluca Pontone,  Mauro Pepi,  Piergiuseppe Agostoni, 
Open Access

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

Kirsten Thiele,  Matthias Rau,  Niels-Ulrik Korbinian Hartmann,  Marcus Möller,  Julia Möllmann,  Joachim Jankowski,  András P. Keszei,  Michael Böhm,  Jürgen Floege,  Nikolaus Marx,  Michael Lehrke, 
Open Access

Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease

Chang Dai,  Bin Kong,  Wei Shuai,  Zheng Xiao,  Tianyou Qin,  Jin Fang,  Yang Gong,  Jun Zhu,  Qi Liu,  Hui Fu,  Hong Meng,  He Huang, 
Open Access

Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care

Daniela Tomasoni,  Julie K.K. Vishram-Nielsen,  Matteo Pagnesi,  Marianna Adamo,  Carlo Mario Lombardi,  Finn Gustafsson,  Marco Metra, 
Open Access

The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure

Anastasia D. Egorova,  Marieke Nederend,  Laurens F. Tops,  Hubert W. Vliegen,  Monique R.M. Jongbloed,  Philippine Kiès, 
Open Access

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin

Stephan Dobner,  Benedikt Bernhard,  Babken Asatryan,  Stephan Windecker,  Stefan Stortecky,  Thomas Pilgrim,  Christoph Gräni,  Lukas Hunziker, 
Open Access

Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice

Zonglin Li,  Fang Lv,  Xin Wen,  Chengcheng Guo,  Li Li,  Xiaoling Cai,  Chu Lin,  Mengqing Zhang,  Wenjia Yang,  Linong Ji,